Vaccine Manufacturing and Procurement in Africa (VMPA) Study
In 2012 a multi-stakeholder effort led by the African Union Commission (AUC) and the United Nations Industrial Development Organization (UNIDO) published the Pharmaceutical Manufacturing Plan for Africa (PMPA), Business Plan (2012). The rationale being that a viable pharmaceutical industry in Africa would not only positively impact the African health systems and capacity to respond to the health needs of the people but will also contribute to the overall socioeconomic development of the continent.
Within this context it was acknowledged that vaccines are a cornerstone of any primary healthcare programme and an essential tool in preventing disease.
Feasibility Study and Strategic Plan Development for Africa Vaccine Manufacturing
Vaccine manufacturing is a complex, time-consuming exercise requiring considerable commitment, and financial and technical resources. The capital investment required is considerable and a long-term future view is essential. While the potential benefits are clear the practical implementation and realization of the desired outcome are not without challenges.
With the support of the United Nations Industrial Development Organization (UNIDO) and the World Health Organization (WHO), AVMI held an expert consultation in October 2014 to discuss options for the development of a strategic approach to this issue.
As a result of this consultation an African-wide study was commissioned. The Vaccine Manufacturing and Procurement in Africa (VMPA) study, initiated in 2015, is an analytical assessment of vaccine manufacturing capacity and procurement mechanisms in Africa focusing on four priority areas:
1. Current and future Vaccine market dynamics.
2. Vaccine procurement mechanisms and associated financing mechanisms.
3. Technical feasibility of establishing sustainable Vaccine manufacturing capacity.
4. Financing and funding mechanisms to establish Vaccine manufacturing
The outputs and outcomes of the study will be utilized to consult and advocate with key stakeholders to advance the development of African vaccine manufacturing considerations. The next steps in the study involve a series of country specific case studies that will further substantiate the final evidence-based report.